The modified vaccinia Ankara-Bavarian Nordic (MVA-BN) vaccine is approved in several countries for use in the prevention of mpox and smallpox in adults. New research suggests it’s also safe and produces an immune response in adolescents, a population affected by the current clade I mpox outbreak.
